Acadia completes $150.0 million sale of rare pediatric disease priority review voucher
Acadia Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher on December 11, 2024, after the Hart-Scott-Rodino waiting period expired. The company received $150.0 million at closing, and one third of the net proceeds are payable to Neuren Pharmaceuticals under a 2023 joint venture and license agreement, so shareholders will receive less than the full amount.
Key points
- Sale closed December 11, 2024, after the Hart-Scott-Rodino waiting period expired.
- Company received $150.0 million at closing under the PRV Transfer Agreement dated November 5, 2024.
- One third of the net proceeds from the voucher sale are payable to Neuren Pharmaceuticals Limited under a July 13, 2023 agreement.
- The voucher was received in March 2023 with FDA approval of DAYBUE (trofinetide) for Rett syndrome.
The filing
Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 11, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.